FUJIFILM Irvine Scientific creates the FUJIFILM “Discovery Research” organization to enable speedy, efficient delivery of FUJIFILM Cellular Dynamics iPSC-derived products through their worldwide distribution channels

Madison, Wis./ Irvine, Calif.,—FUJIFILM Cellular Dynamics, Inc. (FCDI) a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, and FUJIFILM Irvine Scientific, Inc., a leader in cell culture media, announced that beginning April 1, 2020 iCell® products will be sold by the FUJIFILM “Discovery Research” organization (part of FUJIFILM Irvine Scientific). FCDI will continue to lead product innovation, development and manufacture of all iCell products as well as provide the same high-quality logistics and technical support its customers have come to expect.

“At Fujifilm we are dedicated to helping customers accelerate their innovation and discoveries to advance research that can result in drug discovery and development,” said Takeshi Yamamoto, CEO, FUJIFILM Cellular Dynamics, Inc. “By joining forces with FUJIFILM Irvine Scientific to bring our iCell products to customers, we can now leverage synergies and strengths to benefit our partners and ultimately, drive even greater progress in the field.”

Founded in 1970, FUJIFILM Irvine Scientific is a leading developer and manufacturer of cell culture media for biopharmaceuticals, cell and gene therapy, regenerative medicine and reproductive medicine. With a global network of sales and support operations across the United States, European Union, and Asia, FUJIFILM Irvine Scientific is well-positioned to ensure speedy, efficient distribution of FCDI’s products and better serve customers’ needs.

Over the years, FCDI has provided high quality human iPSCs to its partners engaged in drug discovery research to evaluate the safety and efficacy of drug candidates, offering researchers more relevant human biology than the traditional animal models used in preclinical trials. FCDI’s leadership in this field has resulted in over 16 iPSC-derived cell types including neural cells, cardiac cells, and more, and thousands of donor-based disease lines.

While working with FUJIFILM Irvine Scientific’s commercial organization is the first step, the two Fujifilm Group companies will also work together on introducing exciting new joint product kits in the future.

“Fujifilm’s expertise in the life sciences supports drug development from early phase research through to commercialization,” said Yutaka Yamaguchi, CEO, FUJIFILM Irvine Scientific. “Fujifilm Group’s resources allow us to tap our collective pool of knowledge and provide complete end-to-end solutions for our customers. Together, we can do more, faster and better.”

Fujifilm is dedicated to accelerating innovation and services to customers helping advance biological research leading to cellular therapies and drug discovery, by leveraging synergies and strengths between its life science companies.